Predictive modelling in hormone-refractory prostate cancer (HRPC)

Clinical and Translational Oncology

Volumn 11, Issue 2, 2009, Pages 82-85

  Bellmunt, Joaquim ^a   Carles, Joan ^a   Albanell, Joan ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Docetaxel; Hormone refractory prostate cancer; PSADT

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; DOCETAXEL; ESTRAMUSTINE; KETOCONAZOLE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TAXOID;

AGE; ANTIGEN DETECTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; MEDICAL DECISION MAKING; NOMOGRAM; OVERALL SURVIVAL; PROGNOSIS; PROSTATE CANCER; SYMPTOMATOLOGY; DISEASE COURSE; DRUG RESISTANCE; KINETICS; MALE; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; KINETICS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 67449092662     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0318-x     Document Type: Article

References (14)

1. Ferlay J, Bray F, Pisani P et al (2004) GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0
2. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597
3. Crawford ED, Eisenberger MA, McLeod DG et al (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424
4. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45
5. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109
6. Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764
7. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
8. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
9. Ryan CJ, Small EJ (2005) Early versus delayed androgen deprivation for prostate cancer: New fuel for an old debate. J Clin Oncol 23:8225-8231
10. Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245
11. Sternberg CN, Krainer M, Oh WK et al (2007) The medical management of prostate cancer: A multidisciplinary team approach. BJU Int 99:22-27
12. Berthold DR, Pond GR, Roessner M et al (2008) Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 Study. Clin Cancer Res 14:2763-2767
13. Halabi S, Small EJ, Kantoff PW et al (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237
14. Akimoto S, Masai M, Akakura K et al (1995) Tumor marker doubling time in patients with prostate cancer: Determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur Urol 27:207-212